SE9400088D0 - Bacterial receptor structures - Google Patents

Bacterial receptor structures

Info

Publication number
SE9400088D0
SE9400088D0 SE9400088A SE9400088A SE9400088D0 SE 9400088 D0 SE9400088 D0 SE 9400088D0 SE 9400088 A SE9400088 A SE 9400088A SE 9400088 A SE9400088 A SE 9400088A SE 9400088 D0 SE9400088 D0 SE 9400088D0
Authority
SE
Sweden
Prior art keywords
proteins
receptor structures
bacterial receptor
bacterial
receptors
Prior art date
Application number
SE9400088A
Other languages
English (en)
Swedish (sv)
Inventor
Bjoern Nilsson
Per-Aake Nygren
Mathias Uhlen
Original Assignee
Kabi Pharmacia Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kabi Pharmacia Ab filed Critical Kabi Pharmacia Ab
Priority to SE9400088A priority Critical patent/SE9400088D0/xx
Publication of SE9400088D0 publication Critical patent/SE9400088D0/xx
Priority to NZ278991A priority patent/NZ278991A/en
Priority to AT95907175T priority patent/ATE279439T1/de
Priority to AU15487/95A priority patent/AU696186B2/en
Priority to DE69533644T priority patent/DE69533644T2/de
Priority to CA002181042A priority patent/CA2181042C/en
Priority to PCT/SE1995/000034 priority patent/WO1995019374A1/en
Priority to JP51898495A priority patent/JP4089920B2/ja
Priority to EP95907175A priority patent/EP0739353B1/en
Priority to PT95907175T priority patent/PT739353E/pt
Priority to US08/669,360 priority patent/US5831012A/en
Priority to ES95907175T priority patent/ES2225838T3/es
Priority to US09/082,468 priority patent/US6534628B1/en
Priority to US09/568,051 priority patent/US6740734B1/en
Priority to JP2005138021A priority patent/JP2005263810A/ja
Priority to JP2007195296A priority patent/JP4373461B2/ja

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1037—Screening libraries presented on the surface of microorganisms, e.g. phage display, E. coli display
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/305—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F)
    • C07K14/31—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F) from Staphylococcus (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/8215—Microorganisms
    • Y10S435/822—Microorganisms using bacteria or actinomycetales
    • Y10S435/882—Staphylococcus
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/8215—Microorganisms
    • Y10S435/822—Microorganisms using bacteria or actinomycetales
    • Y10S435/882—Staphylococcus
    • Y10S435/883—Staphylococcus aureus
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/82—Proteins from microorganisms
    • Y10S530/825—Bacteria

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Virology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SE9400088A 1994-01-14 1994-01-14 Bacterial receptor structures SE9400088D0 (sv)

Priority Applications (16)

Application Number Priority Date Filing Date Title
SE9400088A SE9400088D0 (sv) 1994-01-14 1994-01-14 Bacterial receptor structures
ES95907175T ES2225838T3 (es) 1994-01-14 1995-01-16 Estructuras de receptor bacteriano.
PCT/SE1995/000034 WO1995019374A1 (en) 1994-01-14 1995-01-16 Bacterial receptor structures
EP95907175A EP0739353B1 (en) 1994-01-14 1995-01-16 Bacterial receptor structures
AU15487/95A AU696186B2 (en) 1994-01-14 1995-01-16 Bacterial receptor structures
DE69533644T DE69533644T2 (de) 1994-01-14 1995-01-16 Rezeptorstrukturen aus bakterien
CA002181042A CA2181042C (en) 1994-01-14 1995-01-16 Bacterial receptor structures
NZ278991A NZ278991A (en) 1994-01-14 1995-01-16 Proteins derived from mutagenesis of surface exposed amino acid domains of natural bacterial receptors
JP51898495A JP4089920B2 (ja) 1994-01-14 1995-01-16 細菌レセプター構造体
AT95907175T ATE279439T1 (de) 1994-01-14 1995-01-16 Rezeptorstrukturen aus bakterien
PT95907175T PT739353E (pt) 1994-01-14 1995-01-16 Estruturas receptoras bacterianas
US08/669,360 US5831012A (en) 1994-01-14 1995-01-16 Bacterial receptor structures
US09/082,468 US6534628B1 (en) 1994-01-14 1998-05-21 Bacterial receptor structures
US09/568,051 US6740734B1 (en) 1994-01-14 2000-05-10 Bacterial receptor structures
JP2005138021A JP2005263810A (ja) 1994-01-14 2005-05-11 細菌レセプター構造体
JP2007195296A JP4373461B2 (ja) 1994-01-14 2007-07-27 細菌レセプター構造体

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9400088A SE9400088D0 (sv) 1994-01-14 1994-01-14 Bacterial receptor structures

Publications (1)

Publication Number Publication Date
SE9400088D0 true SE9400088D0 (sv) 1994-01-14

Family

ID=20392561

Family Applications (1)

Application Number Title Priority Date Filing Date
SE9400088A SE9400088D0 (sv) 1994-01-14 1994-01-14 Bacterial receptor structures

Country Status (12)

Country Link
US (2) US5831012A (xx)
EP (1) EP0739353B1 (xx)
JP (3) JP4089920B2 (xx)
AT (1) ATE279439T1 (xx)
AU (1) AU696186B2 (xx)
CA (1) CA2181042C (xx)
DE (1) DE69533644T2 (xx)
ES (1) ES2225838T3 (xx)
NZ (1) NZ278991A (xx)
PT (1) PT739353E (xx)
SE (1) SE9400088D0 (xx)
WO (1) WO1995019374A1 (xx)

Families Citing this family (336)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9400088D0 (sv) * 1994-01-14 1994-01-14 Kabi Pharmacia Ab Bacterial receptor structures
US6740734B1 (en) 1994-01-14 2004-05-25 Biovitrum Ab Bacterial receptor structures
KR100249442B1 (ko) * 1995-12-27 2000-05-01 시바타 마사하루 스트렙토코커스아갈락티아에ia형또는ib형표면다당을주성분으로하는암전이저해제
GB9722131D0 (en) * 1997-10-20 1997-12-17 Medical Res Council Method
SE9704141D0 (sv) * 1997-11-12 1997-11-12 Sbl Vaccin Ab New protein and nucleotide sequence, encoding said protein
GB9823071D0 (en) * 1998-10-21 1998-12-16 Affibody Technology Ab A method
SE9901379D0 (sv) 1999-04-19 1999-04-19 Pharmacia & Upjohn Ab Receptor structures
US6602977B1 (en) 1999-04-19 2003-08-05 Biovitrum Ab Receptor structures
CA2374013A1 (en) * 1999-05-15 2000-11-23 University Of California, San Diego Protein a based binding domains with desirable activities
US7163686B1 (en) 1999-05-15 2007-01-16 The Regents Of The University Of California Protein A based binding domains with desirable activities
GB9917027D0 (en) * 1999-07-20 1999-09-22 Affibody Technology Sweeden Ab In vitro selection and optional identification of polypeptides using solid support carriers
ATE422369T1 (de) * 1999-12-24 2009-02-15 Genentech Inc Verfahren und zusammensetzungen zur verlängerung der entsorgungshalbwertszeit von biowirksamen verbindungen
GB0017720D0 (en) * 2000-07-19 2000-09-06 Got A Gene Ab Modified virus
WO2002056024A2 (en) * 2001-01-12 2002-07-18 Affibody Ab Detection methods
US20040077017A1 (en) * 2001-01-12 2004-04-22 Amelie Karlstrom Detection methods
DK1390535T3 (da) * 2001-04-26 2010-12-06 Amgen Mountain View Inc Kombinatoriske biblioteker af monomer-domæner
US20050053973A1 (en) * 2001-04-26 2005-03-10 Avidia Research Institute Novel proteins with targeted binding
US20050048512A1 (en) * 2001-04-26 2005-03-03 Avidia Research Institute Combinatorial libraries of monomer domains
US20050089932A1 (en) * 2001-04-26 2005-04-28 Avidia Research Institute Novel proteins with targeted binding
US20030157561A1 (en) * 2001-11-19 2003-08-21 Kolkman Joost A. Combinatorial libraries of monomer domains
US20040175756A1 (en) * 2001-04-26 2004-09-09 Avidia Research Institute Methods for using combinatorial libraries of monomer domains
US7981863B2 (en) 2001-09-19 2011-07-19 Neuronova Ab Treatment of Parkinson's disease with PDGF
FI115343B (fi) * 2001-10-22 2005-04-15 Filtronic Lk Oy Sisäinen monikaista-antenni
US20050069549A1 (en) 2002-01-14 2005-03-31 William Herman Targeted ligands
US20040009530A1 (en) * 2002-01-16 2004-01-15 Wilson David S. Engineered binding proteins
SE0200943D0 (sv) * 2002-03-25 2002-03-25 Amersham Biosciences Ab Mutant protein
US9321832B2 (en) 2002-06-28 2016-04-26 Domantis Limited Ligand
EP1517921B1 (en) * 2002-06-28 2006-06-07 Domantis Limited Dual specific ligands with increased serum half-life
US20060002935A1 (en) 2002-06-28 2006-01-05 Domantis Limited Tumor Necrosis Factor Receptor 1 antagonists and methods of use therefor
US20050074865A1 (en) 2002-08-27 2005-04-07 Compound Therapeutics, Inc. Adzymes and uses thereof
EP1599597B1 (en) * 2003-02-24 2010-08-04 Pritest, Inc. Translucent solid matrix assay device for microarray analysis
US6861251B2 (en) 2003-02-24 2005-03-01 Pritest, Inc. Translucent solid matrix assay device for microarray analysis
US20060177870A1 (en) * 2003-04-28 2006-08-10 Ciphergen Biosystems, Inc Immunoassays
PT2382990E (pt) 2003-04-30 2014-12-29 Univ Zuerich Método para tratamento do cancro usando uma imunotoxina
AU2004253835B2 (en) * 2003-07-04 2009-01-29 Affibody Ab Polypeptides having binding affinity for HER2
US7956165B2 (en) 2003-07-24 2011-06-07 Affisink Biotechnology Ltd. Compositions and methods for purifying and crystallizing molecules of interest
IL157086A0 (en) * 2003-07-24 2004-02-08 Guy Patchornik Multivalent ligand complexes
US20050181398A1 (en) * 2004-01-16 2005-08-18 Fung Eric T. Specific detection of host response protein clusters
JP5634008B2 (ja) 2004-04-06 2014-12-03 アフィボディ・アーベー 新規の使用および方法
US8092549B2 (en) 2004-09-24 2012-01-10 The Invention Science Fund I, Llc Ciliated stent-like-system
US8361013B2 (en) 2004-04-19 2013-01-29 The Invention Science Fund I, Llc Telescoping perfusion management system
US9011329B2 (en) 2004-04-19 2015-04-21 Searete Llc Lumenally-active device
US8512219B2 (en) 2004-04-19 2013-08-20 The Invention Science Fund I, Llc Bioelectromagnetic interface system
US7857767B2 (en) 2004-04-19 2010-12-28 Invention Science Fund I, Llc Lumen-traveling device
US7998060B2 (en) 2004-04-19 2011-08-16 The Invention Science Fund I, Llc Lumen-traveling delivery device
US8353896B2 (en) 2004-04-19 2013-01-15 The Invention Science Fund I, Llc Controllable release nasal system
US7850676B2 (en) 2004-04-19 2010-12-14 The Invention Science Fund I, Llc System with a reservoir for perfusion management
US8337482B2 (en) 2004-04-19 2012-12-25 The Invention Science Fund I, Llc System for perfusion management
US8019413B2 (en) 2007-03-19 2011-09-13 The Invention Science Fund I, Llc Lumen-traveling biological interface device and method of use
BRPI0511755A (pt) * 2004-06-01 2008-01-02 Domantis Ltd composições, fusões e conjugados de drogas e métodos de produção, tratamento e utilização
CA2486285C (en) * 2004-08-30 2017-03-07 Viktor S. Goldmakher Immunoconjugates targeting syndecan-1 expressing cells and use thereof
US7563443B2 (en) * 2004-09-17 2009-07-21 Domantis Limited Monovalent anti-CD40L antibody polypeptides and compositions thereof
KR20070084069A (ko) 2004-10-08 2007-08-24 도만티스 리미티드 Ｔｎｆｒ1에 대한 단일 도메인 항체 및 이의 사용 방법
BRPI0518761A2 (pt) 2004-12-02 2008-12-09 Domantis Ltd fusço de droga, conjugado de droga, Ácido nucleico recombinante, construÇço de Ácido nucleico, cÉlula hospedeira, mÉtodo para produzir uma fusço de droga, composiÇço farmacÊutica, droga, mÉtodo de tratamento e/ou prevenÇço de uma condiÇço em um paciente, mÉtodo de retardo ou prevenÇço de progressço de doenÇa, e, mÉtodo para diminuir a absorÇço de alimentos por um paciente
EP1846444A2 (en) * 2004-12-22 2007-10-24 Lipopeptide AB Agents inhibiting the cathelin-like protein cap18/ll-37
US20070003528A1 (en) 2005-06-29 2007-01-04 Paul Consigny Intracoronary device and method of use thereof
NZ568762A (en) 2005-11-07 2011-11-25 Scripps Research Inst Use of an inhibitor of tissue factor signaling in the manufacture of a medcament for inhibiting or suppressing tissue factor/tissue factor VIIa signaling involving protease activated receptor 2 in a mammal
GB0524788D0 (en) * 2005-12-05 2006-01-11 Affibody Ab Polypeptides
US20110172826A1 (en) * 2005-12-14 2011-07-14 Amodei Dario G Device including altered microorganisms, and methods and systems of use
US20110184387A1 (en) * 2010-01-22 2011-07-28 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Compositions and methods for therapeutic delivery with microorganisms
US8278094B2 (en) 2005-12-14 2012-10-02 The Invention Science Fund I, Llc Bone semi-permeable device
US8734823B2 (en) 2005-12-14 2014-05-27 The Invention Science Fund I, Llc Device including altered microorganisms, and methods and systems of use
US8682619B2 (en) 2005-12-14 2014-03-25 The Invention Science Fund I, Llc Device including altered microorganisms, and methods and systems of use
US20090053790A1 (en) 2006-01-31 2009-02-26 Ishihara Sangyo Kaisha, Ltd. Polypeptide Having Affinity for Envelope Virus Constituent and Use Thereof in Transferring Substance Into Cell
US20120035437A1 (en) 2006-04-12 2012-02-09 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Navigation of a lumen traveling device toward a target
US8160680B2 (en) 2006-04-12 2012-04-17 The Invention Science Fund I, Llc Autofluorescent imaging and target ablation
WO2007139397A1 (en) * 2006-05-26 2007-12-06 Waikatolink Limited Ob fold domains
GB0611116D0 (en) 2006-06-06 2006-07-19 Oxford Genome Sciences Uk Ltd Proteins
MX2009002418A (es) 2006-09-05 2009-04-23 Medarex Inc Anticuerpos para las proteinas morfogenicas oseas y receptores de estas y metodos para su uso.
PT2066351E (pt) 2006-10-02 2015-11-30 Squibb & Sons Llc Anticorpos humanos que se ligam a cxcr4 e utilizações dos mesmos
US20080096233A1 (en) * 2006-10-20 2008-04-24 Robotti Karla M Isolation Of Immune Complexes
GB0621513D0 (en) 2006-10-30 2006-12-06 Domantis Ltd Novel polypeptides and uses thereof
CA2671457C (en) 2006-12-01 2017-09-26 Medarex, Inc. Human antibodies that bind cd22 and uses thereof
US8198043B2 (en) * 2006-12-08 2012-06-12 General Electric Company Two helix binders
US7981691B2 (en) * 2006-12-08 2011-07-19 General Electric Company Two helix binders
US7989216B2 (en) * 2006-12-08 2011-08-02 General Electric Company Two helix binders
US7977118B2 (en) * 2006-12-08 2011-07-12 General Electric Company Two helix binders
CL2007003622A1 (es) 2006-12-13 2009-08-07 Medarex Inc Anticuerpo monoclonal humano anti-cd19; composicion que lo comprende; y metodo de inhibicion del crecimiento de celulas tumorales.
KR20090088946A (ko) 2006-12-14 2009-08-20 메다렉스, 인코포레이티드 씨디70에 결합하는 인간 항체 및 이의 용도
WO2008104803A2 (en) 2007-02-26 2008-09-04 Oxford Genome Sciences (Uk) Limited Proteins
EP2121745A2 (en) 2007-02-26 2009-11-25 Oxford Genome Sciences (UK) Limited Proteins
US8303960B2 (en) * 2007-02-27 2012-11-06 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Radiolabeled affibody molecules
WO2008124632A1 (en) * 2007-04-04 2008-10-16 Massachusetts Institute Of Technology Amphiphilic compound assisted nanoparticles for targeted delivery
GB0708376D0 (en) 2007-05-01 2007-06-06 Alligator Bioscience Ab Novel polypeptides and uses thereof
MX2009013269A (es) 2007-06-05 2010-04-21 Univ Yale Inhibidores de receptor de cinasas de tirosina y metodos de uso de los mismos.
SG149759A1 (en) 2007-07-10 2009-02-27 Millipore Corp Media for affinity chromatography
EP2183275B1 (en) 2007-08-03 2014-10-29 Affibody AB Igf-1r binding polypeptides and their use
EP2192922A4 (en) 2007-09-17 2010-09-29 Univ California INTERNALIZING HUMAN MONOCLONAL ANTIBODIES TARGING PROSTATE <I> IN SITU CANCER CELLS </ I>
MX2010003099A (es) 2007-09-21 2010-05-17 Univ California Interferon de objetivo demuestra actividades potentes apoptoticas y antitumorales.
TWI489993B (zh) 2007-10-12 2015-07-01 Novartis Ag 骨硬化素（ｓｃｌｅｒｏｓｔｉｎ）抗體組合物及使用方法
GB2453589A (en) 2007-10-12 2009-04-15 King S College London Protease inhibition
EP3536336A1 (en) 2007-11-30 2019-09-11 Siemens Healthcare Diagnostics Inc. Adiponectin receptor fragments and methods of use
EP2077272A1 (en) * 2007-12-21 2009-07-08 Affibody AB Polypeptide libraries with a predetermined scaffold
US9187535B2 (en) 2007-12-19 2015-11-17 Affibody Ab Polypeptide derived from protein A and able to bind PDGF
EP2072525A1 (en) 2007-12-21 2009-06-24 Affibody AB New polypeptides having affinity for HER2
WO2009080829A1 (en) * 2007-12-26 2009-07-02 Biotest Ag Agents targeting cd138 and uses thereof
AR069980A1 (es) * 2007-12-26 2010-03-03 Biotest Ag Inmunoconjugados dirigidos contra cd 138 y sus usos
WO2009080832A1 (en) * 2007-12-26 2009-07-02 Biotest Ag Methods and agents for improving targeting of cd138 expressing tumor cells
EP2238169A1 (en) * 2007-12-26 2010-10-13 Biotest AG Method of decreasing cytotoxic side-effects and improving efficacy of immunoconjugates
WO2009146099A2 (en) 2008-04-02 2009-12-03 Georgia State University Research Foundation, Inc. Contrast agents, methods for preparing contrast agents, and methods of imaging
EP2700651B1 (en) 2008-07-18 2019-04-10 Bristol-Myers Squibb Company Compositions monovalent for CD28 binding and methods of use
US20100022497A1 (en) * 2008-07-24 2010-01-28 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Method for treating or preventing a cardiovascular disease or condition utilizing estrogen receptor modulators based on APOE allelic profile of a mammalian subject
US20100022494A1 (en) * 2008-07-24 2010-01-28 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Method, device, and kit for maintaining physiological levels of steroid hormone in a subject
US20100061976A1 (en) * 2008-07-24 2010-03-11 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Method for treating or preventing osteoporosis by reducing follicle stimulating hormone to cyclic physiological levels in a mammalian subject
US20100022991A1 (en) * 2008-07-24 2010-01-28 Searete Llc, A Limited Liability Corporation Of The State Of Delaware System and device for maintaining physiological levels of steroid hormone in a subject
KR20110036638A (ko) 2008-07-25 2011-04-07 리차드 더블유. 와그너 단백질 스크리닝 방법
MX356218B (es) 2008-08-05 2018-05-18 Novartis Ag Composiciones y métodos para anticuerpos que se dirigen a la proteína de complemento c5.
US8592555B2 (en) 2008-08-11 2013-11-26 Emd Millipore Corporation Immunoglobulin-binding proteins with improved specificity
US9187330B2 (en) 2008-09-15 2015-11-17 The Invention Science Fund I, Llc Tubular nanostructure targeted to cell membrane
US20100137246A1 (en) * 2008-12-02 2010-06-03 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Anti-inflammatory compositions and methods
US20100137844A1 (en) * 2008-12-02 2010-06-03 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Delivery devices for modulating inflammation
US20100136095A1 (en) * 2008-12-02 2010-06-03 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Systems for modulating inflammation
US20100136094A1 (en) * 2008-12-02 2010-06-03 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Systems for modulating inflammation
US20100136097A1 (en) * 2008-12-02 2010-06-03 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Systems for modulating inflammation
US20100135983A1 (en) * 2008-12-02 2010-06-03 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Anti-inflammatory compositions and methods
US20100136096A1 (en) * 2008-12-02 2010-06-03 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Systems for modulating inflammation
US20120041286A1 (en) 2008-12-04 2012-02-16 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Systems, devices, and methods including implantable devices with anti-microbial properties
JP5985826B2 (ja) 2008-12-16 2016-09-06 ノバルティス アーゲー 酵母ディスプレイ系
US20120165650A1 (en) 2010-12-22 2012-06-28 General Electric Company Her2 binders
SG162687A1 (en) 2008-12-24 2010-07-29 Millipore Corp Caustic stable chromatography ligands
WO2010084408A2 (en) 2009-01-21 2010-07-29 Oxford Biotherapeutics Ltd. Pta089 protein
US8167871B2 (en) 2009-02-25 2012-05-01 The Invention Science Fund I, Llc Device for actively removing a target cell from blood or lymph of a vertebrate subject
US8721618B2 (en) 2009-02-25 2014-05-13 The Invention Science Fund I, Llc Device for actively removing a target cell from blood or lymph of a vertebrate subject
US8430831B2 (en) * 2009-02-25 2013-04-30 The Invention Science Fund I, Llc Device, system, and method for controllably reducing inflammatory mediators in a subject
US8317737B2 (en) * 2009-02-25 2012-11-27 The Invention Science Fund I, Llc Device for actively removing a target component from blood or lymph of a vertebrate subject
KR101769160B1 (ko) 2009-03-05 2017-08-17 옥스포드 바이오테라퓨틱스 리미티드 Ｃａｄｍ１에 특이적인 완전 인간 항체
GB0904355D0 (en) 2009-03-13 2009-04-29 Imp Innovations Ltd Biological materials and uses thereof
US9834815B2 (en) 2009-03-25 2017-12-05 Life Technologies Corporation Discriminatory positive/extraction control DNA
US8728479B2 (en) 2009-03-31 2014-05-20 The Trustees Of The University Of Pennsylvania Antigen-binding proteins comprising recombinant protein scaffolds
WO2010112193A1 (en) 2009-04-02 2010-10-07 Roche Glycart Ag Multispecific antibodies comprising full length antibodies and single chain fab fragments
US9181339B2 (en) 2009-04-20 2015-11-10 Oxford Bio Therapeutics Ltd. Antibodies specific to cadherin-17
EP2422199B1 (en) 2009-04-23 2018-07-25 Siemens Healthcare Diagnostics Inc. Monomeric and dimeric forms of adiponectin receptor fragments and methods of use
PT2424895T (pt) 2009-04-27 2017-12-15 Novartis Ag Composições e métodos para aumentar o crescimento muscular
MX2011011338A (es) 2009-04-27 2012-04-19 Novartis Ag Composiciones y metodos de uso para anticuerpos terapeuticos especificos para la subunidad beta1 del receptor de il-12.
US8154285B1 (en) 2009-05-29 2012-04-10 The Invention Science Fund I, Llc Non-external static magnetic field imaging systems, devices, methods, and compositions
US8106655B2 (en) * 2009-05-29 2012-01-31 The Invention Science Fund I, Llc Multiplex imaging systems, devices, methods, and compositions including ferromagnetic structures
US8058872B2 (en) 2009-05-29 2011-11-15 The Invention Science Fund I, Llc Systems, devices, methods, and compositions including functionalized ferromagnetic structures
US20100303733A1 (en) * 2009-05-29 2010-12-02 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Systems, devices, methods, and compositions including ferromagnetic structures
US8063636B2 (en) * 2009-05-29 2011-11-22 The Invention Science Fund I, Llc Systems, devices, methods, and compositions including targeted ferromagnetic structures
IE20090514A1 (en) 2009-07-06 2011-02-16 Opsona Therapeutics Ltd Humanised antibodies and uses therof
DK2464657T3 (en) 2009-08-10 2015-06-29 Morphosys Ag New screening strategies for the identification of antibodies or fragments thereof which bind an antigen with enzymatic activity
US9024766B2 (en) * 2009-08-28 2015-05-05 The Invention Science Fund, Llc Beverage containers with detection capability
US8810417B2 (en) * 2009-08-28 2014-08-19 The Invention Science Fund I, Llc Beverage immersate with detection capability
WO2011029823A1 (en) 2009-09-09 2011-03-17 Novartis Ag Monoclonal antibody reactive with cd63 when expressed at the surface of degranulated mast cells
NZ598962A (en) 2009-09-16 2014-12-24 Genentech Inc Coiled coil and/or tether containing protein complexes and uses thereof
JP5954876B2 (ja) 2009-10-13 2016-07-20 ナノストリング テクノロジーズ， インコーポレイテッド ナノレポーターによるタンパク質の検出
WO2011047083A1 (en) 2009-10-13 2011-04-21 Oxford Biotherapeutics Ltd. Antibodies against epha10
US20120282177A1 (en) 2009-11-02 2012-11-08 Christian Rohlff ROR1 as Therapeutic and Diagnostic Target
US20120282276A1 (en) 2009-11-05 2012-11-08 The Regents Of The University Of Michigan Biomarkers predictive of progression of fibrosis
WO2011080050A2 (en) 2009-12-11 2011-07-07 Novartis Ag Binding molecules
WO2011074717A1 (ko) * 2009-12-15 2011-06-23 Choe Muhyeon 단량체에 접착특이성이 있는 접착체의 반복사슬과 다수단량체의 복합체 내에서의 결합 가교의 생성 증가를 통한 이량체 및 다량체의 생산방법
JP2013519869A (ja) 2010-02-10 2013-05-30 ノバルティス アーゲー 筋肉成長のための方法および化合物
AR080793A1 (es) 2010-03-26 2012-05-09 Roche Glycart Ag Anticuerpos biespecificos
KR101860963B1 (ko) 2010-04-23 2018-05-24 제넨테크, 인크. 이종다량체 단백질의 생산
MX2012012927A (es) 2010-05-06 2013-05-01 Novartis Ag Composiciones y metodos de uso para anticuerpos multivalentes terapeuticos de proteina relacionada con lipoproteina de baja densidad 6 (lrp6).
EA201291180A1 (ru) 2010-05-06 2013-05-30 Новартис Аг Композиции и способы применения терапевтических антител против белка, родственного рецептору липопротеинов низкой плотности 6 (lrp6)
CN110437320B (zh) 2010-07-09 2023-10-20 阿菲博迪公司 多肽
WO2012009705A1 (en) 2010-07-15 2012-01-19 Zyngenia, Inc. Ang-2 binding complexes and uses thereof
JP2013537539A (ja) 2010-08-13 2013-10-03 ジェネンテック， インコーポレイテッド 疾患の治療のためのＩＬ−１β及びＩＬ−１８に対する抗体
KR102027011B1 (ko) 2010-08-20 2019-09-30 노파르티스 아게 표피 성장 인자 수용체 3 (ｈｅｒ3)에 대한 항체
KR101586128B1 (ko) 2010-08-24 2016-01-15 에프. 호프만-라 로슈 아게 디술피드 안정화 ― Ｆｖ 단편을 포함하는 이중특이적 항체
ES2678145T3 (es) 2010-08-24 2018-08-09 Abbott Laboratories Anticuerpos específicos contra la proteína del núcleo del VIH y usos de los mismos
SG188666A1 (en) 2010-09-30 2013-05-31 Agency Science Tech & Res Methods and reagents for detection and treatment of esophageal metaplasia
JP2013543384A (ja) 2010-10-05 2013-12-05 ノバルティス アーゲー 抗−ｉｌ１２ｒベータ１抗体ならびに自己免疫性および炎症性疾患の処置おけるその使用
EP2655404B1 (en) 2010-12-21 2017-11-15 The University of Western Ontario Novel alkali-resistant variants of protein a and their use in affinity chromatography
WO2012086660A1 (ja) 2010-12-21 2012-06-28 Jsr株式会社 アフィニティークロマトグラフィー用担体およびイムノグロブリンを単離する方法
SG191153A1 (en) 2010-12-23 2013-07-31 Hoffmann La Roche Polypeptide-polynucleotide-complex and its use in targeted effector moiety delivery
EP2670863B1 (en) 2011-01-31 2018-06-27 H. Hoffnabb-La Roche Ag Methods of identifying multiple epitopes in cells
MX355255B (es) 2011-02-04 2018-04-11 Genentech Inc Variantes de fc y métodos para su producción.
US10689447B2 (en) 2011-02-04 2020-06-23 Genentech, Inc. Fc variants and methods for their production
EP2673297A2 (en) 2011-02-11 2013-12-18 Zyngenia, Inc. Monovalent and multivalent multispecific complexes and uses thereof
GB201114858D0 (en) 2011-08-29 2011-10-12 Nvip Pty Ltd Anti-nerve growth factor antibodies and methods of using the same
SG194793A1 (en) 2011-05-06 2013-12-30 Nvip Pty Ltd Anti-nerve growth factor antibodies and methods of preparing and using the same
PT3498732T (pt) 2011-05-06 2022-02-02 Zoetis Services Llc Anticorpos anti-fator de crescimento do nervo e método para preparação e utilização dos mesmos
CA2834983C (en) 2011-05-06 2020-11-17 Nvip Pty Ltd Anti-nerve growth factor antibodies and methods of preparing and using the same
WO2012162561A2 (en) 2011-05-24 2012-11-29 Zyngenia, Inc. Multivalent and monovalent multispecific complexes and their uses
SG10201604559TA (en) 2011-06-08 2016-07-28 Emd Millipore Corp Chromatography matrices including novel staphylococcus aureus protein a based ligands
WO2012172495A1 (en) 2011-06-14 2012-12-20 Novartis Ag Compositions and methods for antibodies targeting tem8
US9447178B2 (en) 2011-06-28 2016-09-20 Oxford Biotherapeutics Ltd. Therapeutic and diagnostic target
SG10201605323SA (en) 2011-06-28 2016-08-30 Oxford Biotherapeutics Ltd Antibodies to adp-ribosyl cyclase 2
PT2726099T (pt) 2011-07-01 2018-11-13 Novartis Ag Método para o tratamento de distúrbios metabólicos
US9238689B2 (en) 2011-07-15 2016-01-19 Morpho Sys AG Antibodies that are cross-reactive for macrophage migration inhibitory factor (MIF) and D-dopachrome tautomerase (D-DT)
US9701749B2 (en) 2011-08-11 2017-07-11 Ono Pharmaceutical Co., Ltd. Therapeutic agent for autoimmune diseases comprising PD-1 agonist
PL3418306T3 (pl) 2011-10-11 2024-04-15 F. Hoffmann-La Roche Ag Ulepszone składanie przeciwciał dwuswoistych
CN109111523B (zh) 2011-10-14 2022-06-07 诺华股份有限公司 用于Wnt途径相关疾病的抗体和方法
WO2013077573A1 (ko) 2011-11-25 2013-05-30 서울대학교산학협력단 Ｂ형 간염 바이러스 유래 ｃｉｓ-작용 조절 엘리먼트 및 그 용도
BR112014013568A8 (pt) 2011-12-05 2017-06-13 Novartis Ag anticorpos para o receptor do fator de crescimento epidermal 3 (her3) direcionados para o domínio ii do her3
EP3590538A1 (en) 2011-12-05 2020-01-08 Novartis AG Antibodies for epidermal growth factor receptor 3 (her3)
JP6218746B2 (ja) 2011-12-08 2017-10-25 バイオテスト・アクチエンゲゼルシヤフト Ｃｄ１３８を標的とする免疫複合体の使用
PE20150159A1 (es) 2011-12-21 2015-02-08 Novartis Ag Composiciones y metodos para anticuerpos que actuan sobre el factor p
CN104105711B (zh) 2012-02-10 2018-11-30 弗·哈夫曼-拉罗切有限公司 单链抗体及其他异多聚体
SI2817329T1 (sl) 2012-02-20 2019-04-30 Swedish Orphan Biovitrum Ab (Publ) Polipeptidi, ki se vežejo na človeški komplement c5
CA2865243A1 (en) 2012-02-23 2013-08-29 President And Fellows Of Harvard College Modified microbial toxin receptor for delivering agents into cells
KR20210075191A (ko) 2012-03-28 2021-06-22 애피바디 에이비 경구투여
BR112014028368A2 (pt) 2012-06-27 2017-11-14 Hoffmann La Roche método de produção de conjugado de região fc de anticorpo, conjugado de região fc de anticorpo e formulação farmacêutica
KR20150023889A (ko) 2012-06-27 2015-03-05 에프. 호프만-라 로슈 아게 2 개 이상의 상이한 결합 단위를 함유하는 맞춤-제작된 고도로 선별적이고 다중-특이적인 표적화 단위의 선별 및 제조 방법 및 이의 용도
WO2014013016A1 (en) 2012-07-20 2014-01-23 Affibody Ab Method for determining the her2 status of a malignancy
GB201213652D0 (en) 2012-08-01 2012-09-12 Oxford Biotherapeutics Ltd Therapeutic and diagnostic target
JP6525872B2 (ja) 2012-08-08 2019-06-05 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 細胞中の複数のエピトープを同定するためのダイナミックレンジを高めること
JOP20200308A1 (ar) 2012-09-07 2017-06-16 Novartis Ag جزيئات إرتباط il-18
CN111763247A (zh) 2012-09-25 2020-10-13 阿菲博迪公司 白蛋白结合多肽
WO2014076179A1 (en) 2012-11-14 2014-05-22 Affibody Ab New polypeptide
WO2014084859A1 (en) 2012-11-30 2014-06-05 Novartis Ag Molecules and methods for modulating tmem16a activities
PL2928921T3 (pl) 2012-12-05 2021-06-28 Novartis Ag Kompozycje i sposoby dla przeciwciał celujących w epo
EP2931293B1 (en) 2012-12-12 2019-02-20 University Of Virginia Patent Foundation Compositions and methods for regulating erythropoiesis
US9897611B2 (en) 2012-12-27 2018-02-20 National Institute Of Advanced Industrial Science And Technology Molecule library constructed on the basis of backbone structure of microprotein
WO2014120916A1 (en) 2013-02-01 2014-08-07 Bristol-Myers Squibb Company Pegylated domain antibodies monovalent for cd28 binding and methods of use
WO2015198217A2 (en) 2013-02-08 2015-12-30 Novartis Ag Compositions and methods for long-acting antibodies targeting il-17
ES2758473T3 (es) 2013-02-08 2020-05-05 Novartis Ag Anticuerpos anti-IL-17A y su uso en el tratamiento de trastornos autoinmunitarios e inflamatorios
GB201302447D0 (en) 2013-02-12 2013-03-27 Oxford Biotherapeutics Ltd Therapeutic and diagnostic target
AU2014223824B2 (en) 2013-02-28 2020-02-27 Albert Einstein College Of Medicine, Inc. Tuberculosis biomarkers and uses thereof
WO2014141064A1 (en) 2013-03-13 2014-09-18 Novartis Ag Notch2 binding molecules for treating respiratory diseases
EP2970479B1 (en) 2013-03-14 2019-04-24 Novartis AG Antibodies against notch 3
WO2014145252A2 (en) 2013-03-15 2014-09-18 Milone Michael C Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy
CN105451767B (zh) 2013-03-15 2019-10-18 泽恩格尼亚股份有限公司 多价和单价多特异性复合物及其用途
GB201311031D0 (en) * 2013-06-20 2013-08-07 Queen Mary & Westfield College Method
AR096601A1 (es) 2013-06-21 2016-01-20 Novartis Ag Anticuerpos del receptor 1 de ldl oxidado similar a lectina y métodos de uso
UY35620A (es) 2013-06-21 2015-01-30 Novartis Ag Anticuerpos del receptor 1 de ldl oxidado similar a lectina y métodos de uso
US10208125B2 (en) 2013-07-15 2019-02-19 University of Pittsburgh—of the Commonwealth System of Higher Education Anti-mucin 1 binding agents and uses thereof
PE20160671A1 (es) 2013-08-02 2016-07-09 Pfizer Anticuerpos anti-cxcr4 y conjugados de anticuerpo y farmaco
JP2016528247A (ja) 2013-08-14 2016-09-15 ノバルティス アーゲー 孤発性封入体筋炎を治療する方法
US10203327B2 (en) 2013-11-05 2019-02-12 Novartis Ag Organic compounds
US10167322B2 (en) 2013-12-20 2019-01-01 Affibody Ab Engineered albumin binding polypeptide
EP3087101B1 (en) 2013-12-20 2024-06-05 Novartis AG Regulatable chimeric antigen receptor
US20170081411A1 (en) 2014-03-15 2017-03-23 Novartis Ag Regulatable chimeric antigen receptor
TW201622746A (zh) 2014-04-24 2016-07-01 諾華公司 改善或加速髖部骨折術後身體復原之方法
KR20230164192A (ko) 2014-05-06 2023-12-01 제넨테크, 인크. 포유동물 세포를 사용한 이종다량체 단백질의 생산
US11542488B2 (en) 2014-07-21 2023-01-03 Novartis Ag Sortase synthesized chimeric antigen receptors
WO2016019300A1 (en) 2014-07-31 2016-02-04 Novartis Ag Subset-optimized chimeric antigen receptor-containing t-cells
JP6649358B2 (ja) 2014-08-07 2020-02-19 ノバルティス アーゲー アンジオポエチン様４抗体および使用法
TW201613977A (en) 2014-08-07 2016-04-16 Novartis Ag Angiopoetin-like 4 (ANGPTL4) antibodies and methods of use
EP3194443B1 (en) 2014-09-17 2021-07-14 Novartis AG Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy
MA41044A (fr) 2014-10-08 2017-08-15 Novartis Ag Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
US11566082B2 (en) 2014-11-17 2023-01-31 Cytiva Bioprocess R&D Ab Mutated immunoglobulin-binding polypeptides
PL3227332T3 (pl) 2014-12-03 2020-06-15 F. Hoffmann-La Roche Ag Wielospecyficzne przeciwciała
US20180320241A1 (en) 2014-12-19 2018-11-08 Roche Sequencing Solutions, Inc. Methods for identifying multiple epitopes in selected sub-populations of cells
UY36449A (es) 2014-12-19 2016-07-29 Novartis Ag Composiciones y métodos para anticuerpos dirigidos a bmp6
WO2016105542A2 (en) 2014-12-24 2016-06-30 Neximmune, Inc Nanoparticle compositions and methods for immunotherapy
ES2901273T3 (es) 2015-04-06 2022-03-21 Subdomain Llc Polipéptidos que contienen dominios de unión de novo y usos de los mismos
EP3280729B1 (en) 2015-04-08 2022-04-27 Novartis AG Cd20 therapies, cd22 therapies, and combination therapies with a cd19 chimeric antigen receptor (car) - expressing cell
BR112017021484A2 (pt) 2015-06-05 2018-07-03 Novartis Ag anticorpos de direcionamento à proteína morfogenética óssea 9 (bmp9) e métodos para os mesmos
JOP20200312A1 (ar) 2015-06-26 2017-06-16 Novartis Ag الأجسام المضادة للعامل xi وطرق الاستخدام
JP2018528763A (ja) 2015-07-31 2018-10-04 リサーチ インスティチュート アット ネイションワイド チルドレンズ ホスピタル バイオフィルムの除去のためのペプチドおよび抗体
EP3331914A1 (en) 2015-08-03 2018-06-13 Novartis AG Methods of treating fgf21-associated disorders
UY36889A (es) 2015-09-09 2017-04-28 Novartis Ag Moléculas de unión a linfopoyetina estromal timica (tslp) y métodos de uso de las moléculas
EP3842457A1 (en) 2015-09-09 2021-06-30 Novartis AG Thymic stromal lymphopoietin (tslp)-binding molecules and methods of using the molecules
WO2017066719A2 (en) 2015-10-14 2017-04-20 Research Institute At Nationwide Children's Hospital Hu specific interfering agents
EP3371311B1 (en) 2015-11-06 2021-07-21 Orionis Biosciences BV Bi-functional chimeric proteins and uses thereof
WO2017087825A1 (en) 2015-11-19 2017-05-26 Asclepix Therapeutics, Llc. Peptides with anti-angiogenic, anti-lymphangiogenic, and anti-edemic properties and nanoparticle formulations
EP3383920B1 (en) 2015-11-30 2024-01-10 The Regents of the University of California Tumor-specific payload delivery and immune activation using a human antibody targeting a highly specific tumor cell surface antigen
WO2017103895A1 (en) 2015-12-18 2017-06-22 Novartis Ag Antibodies targeting cd32b and methods of use thereof
WO2017121836A1 (en) 2016-01-15 2017-07-20 Thermo Fisher Scientific Baltics Uab Thermophilic dna polymerase mutants
US10988538B2 (en) 2016-02-05 2021-04-27 Orionis Biosciences BV Bispecific signaling agents and uses thereof
EP3426278B1 (en) 2016-03-07 2024-01-03 Vib Vzw Cd20 binding single domain antibodies
KR20170108203A (ko) 2016-03-16 2017-09-27 주식회사 피플바이오 응집형-형성 폴리펩타이드의 응집형을 검출하는 방법
EP3448887A1 (en) 2016-04-27 2019-03-06 Novartis AG Antibodies against growth differentiation factor 15 and uses thereof
CN110199019A (zh) 2016-05-02 2019-09-03 Encodia有限公司 采用核酸编码的大分子分析
ES2874974T3 (es) 2016-05-11 2021-11-05 Cytiva Bioprocess R & D Ab Matriz de separación
US10703774B2 (en) 2016-09-30 2020-07-07 Ge Healthcare Bioprocess R&D Ab Separation method
US10889615B2 (en) 2016-05-11 2021-01-12 Cytiva Bioprocess R&D Ab Mutated immunoglobulin-binding polypeptides
JP7106187B2 (ja) 2016-05-11 2022-07-26 サイティバ・バイオプロセス・アールアンドディ・アクチボラグ 分離マトリックスを保存する方法
US10654887B2 (en) 2016-05-11 2020-05-19 Ge Healthcare Bio-Process R&D Ab Separation matrix
US10730908B2 (en) 2016-05-11 2020-08-04 Ge Healthcare Bioprocess R&D Ab Separation method
ES2909833T3 (es) 2016-05-11 2022-05-10 Cytiva Bioprocess R & D Ab Método de limpieza y/o desinfección de una matriz de separación
CA3023883A1 (en) 2016-05-13 2017-11-16 Orionis Biosciences Nv Targeted mutant interferon-beta and uses thereof
US11753463B2 (en) 2016-05-13 2023-09-12 Orionis Biosciences BV Therapeutic targeting of non-cellular structures
TW201802121A (zh) 2016-05-25 2018-01-16 諾華公司 抗因子XI/XIa抗體之逆轉結合劑及其用途
AU2017283787B2 (en) 2016-06-15 2020-09-17 Novartis Ag Methods for treating disease using inhibitors of bone morphogenetic protein 6 (BMP6)
CA3038809A1 (en) 2016-10-04 2018-04-12 Asclepix Therapeutics, Llc. Compounds and methods for activating tie2 signaling
JP7204643B2 (ja) 2016-10-24 2023-01-16 オリオニス バイオサイエンシズ ビーブイ 標的変異インターフェロン－ガンマおよびその使用
EP3551766B1 (en) 2016-12-12 2022-09-14 Cepheid Integrated immuno-pcr and nucleic acid analysis in an automated reaction cartridge
BR112019012667A2 (pt) 2016-12-23 2020-02-11 Novartis Ag Anticorpos do fator xi e métodos de uso
WO2018129078A1 (en) 2017-01-04 2018-07-12 Research Institute At Nationwide Children's Hospital Dnabii vaccines and antibodies with enhanced activity
EP3576765A4 (en) 2017-02-06 2020-12-02 Orionis Biosciences, Inc. TARGETED ENGINEERING INTERFERON AND USES OF IT
JP7476467B2 (ja) 2017-02-06 2024-05-01 オリオンズ バイオサイエンス ビーブイ 標的化キメラタンパク質及びその使用
EP3580230A1 (en) 2017-02-07 2019-12-18 VIB vzw Immune-cell targeted bispecific chimeric proteins and uses thereof
WO2018146594A1 (en) 2017-02-08 2018-08-16 Novartis Ag Fgf21 mimetic antibodies and uses thereof
JP2020510432A (ja) 2017-03-02 2020-04-09 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル Ｎｅｃｔｉｎ−４への特異性を有する抗体及びその使用
AU2018236271B2 (en) 2017-03-15 2023-12-21 Research Institute At Nationwide Children's Hospital Composition and methods for disruption of bacterial biofilms without accompanying inflammation
EP3600415A1 (en) 2017-03-24 2020-02-05 Novartis AG Methods for preventing and treating heart disease
KR102014056B1 (ko) 2017-04-18 2019-08-27 앱클론(주) 단백질의 순도 및 항원에 대한 친화성이 향상된 폴리펩티드, 이의 항체 또는 항원 결합 단편과의 복합체, 및 이들의 제조방법
WO2018229715A1 (en) 2017-06-16 2018-12-20 Novartis Ag Compositions comprising anti-cd32b antibodies and methods of use thereof
WO2019002178A1 (en) 2017-06-26 2019-01-03 Thermo Fisher Scientific Baltics Uab DNA MUTANTS THERMOPHILIC POLYMERASES
JP2020525421A (ja) 2017-06-28 2020-08-27 ノバルティス アーゲー 尿失禁を予防及び治療するための方法
US11674959B2 (en) 2017-08-03 2023-06-13 The Johns Hopkins University Methods for identifying and preparing pharmaceutical agents for activating Tie1 and/or Tie2 receptors
WO2019081983A1 (en) 2017-10-25 2019-05-02 Novartis Ag CD32B TARGETING ANTIBODIES AND METHODS OF USE
KR102556494B1 (ko) 2017-10-31 2023-07-18 엔코디아, 인코포레이티드 핵산 암호화 및/또는 표지를 이용한 분석용 키트
CA3082410A1 (en) 2017-11-14 2019-05-23 Arcellx, Inc. Multifunctional immune cell therapies
WO2019099433A2 (en) 2017-11-14 2019-05-23 Arcellx, Inc. D-domain containing polypeptides and uses thereof
US11464803B2 (en) 2017-11-14 2022-10-11 Arcellx, Inc. D-domain containing polypeptides and uses thereof
BR112020010016A2 (pt) 2017-11-22 2020-11-10 Novartis Ag agentes de ligação de reversão para anticorpos antifator xi/xia e usos dos mesmos
WO2019122200A1 (en) 2017-12-22 2019-06-27 Thermo Fisher Scientific Baltics Uab Polymerase chain reaction composition comprising amines
KR20200128533A (ko) 2018-02-05 2020-11-13 오리오니스 바이오사이언시즈 인코포레이티드 섬유아세포 결합제 및 이의 용도
CN111989342A (zh) 2018-04-18 2020-11-24 艾克隆株式会社 开关分子以及可转换嵌合抗原受体
TW202015726A (zh) 2018-05-30 2020-05-01 瑞士商諾華公司 Ｅｎｔｐｄ２抗體、組合療法、及使用該等抗體和組合療法之方法
DE202019005887U1 (de) 2018-07-03 2023-06-14 Marengo Therapeutics, Inc. Anti-TCR-Antikörpermoleküle und Verwendungen davon
EP3626265A1 (en) 2018-09-21 2020-03-25 INSERM (Institut National de la Santé et de la Recherche Médicale) Anti-human cd45rc antibodies and uses thereof
WO2020069409A1 (en) 2018-09-28 2020-04-02 Novartis Ag Cd19 chimeric antigen receptor (car) and cd22 car combination therapies
US20220047633A1 (en) 2018-09-28 2022-02-17 Novartis Ag Cd22 chimeric antigen receptor (car) therapies
AU2019355194A1 (en) 2018-10-05 2021-04-22 Research Institute At Nationwide Children's Hospital Compositions and methods for enzymatic disruption of bacterial biofilms
AR117343A1 (es) 2018-12-18 2021-07-28 Novartis Ag AGENTES DE UNIÓN REVERSIBLE PARA ANTICUERPOS ANTI-FACTOR XI / XIa Y USOS DE LOS MISMOS
JP2022521723A (ja) 2019-02-15 2022-04-12 インテグラル・モレキュラー・インコーポレイテッド クローディン６抗体及びその使用
US11254736B2 (en) 2019-02-15 2022-02-22 Integral Molecular, Inc. Antibodies comprising a common light chain and uses thereof
JP2022524052A (ja) 2019-03-08 2022-04-27 オックスフォード ジェネティクス リミテッド 抗体の選択方法
GB201903233D0 (en) 2019-03-08 2019-04-24 Oxford Genetics Ltd Method of selecting for antibodies
WO2020198075A2 (en) 2019-03-22 2020-10-01 Reflexion Pharmaceuticals, Inc. Multivalent d-peptidic compounds for target proteins
CN114989298A (zh) 2019-03-22 2022-09-02 反射制药有限公司 针对vegf的d-肽化合物
EP3963070A4 (en) 2019-04-30 2023-02-22 Encodia, Inc. METHODS OF PREPARATION OF ANALYTES AND RELATED KITS
EP3972997A1 (en) 2019-05-20 2022-03-30 Institut National de la Santé et de la Recherche Médicale (INSERM) Novel anti-cd25 antibodies
KR20220030956A (ko) 2019-07-05 2022-03-11 오노 야꾸힝 고교 가부시키가이샤 Pd-1/cd3 이중 특이성 단백질에 의한 혈액암 치료
JP2022540083A (ja) 2019-07-08 2022-09-14 リサーチ インスティチュート アット ネイションワイド チルドレンズ ホスピタル バイオフィルムを破壊するための抗体組成物
EP4011918A4 (en) 2019-08-08 2023-08-23 ONO Pharmaceutical Co., Ltd. DUAL SPECIFIC PROTEIN
TW202124446A (zh) 2019-09-18 2021-07-01 瑞士商諾華公司 與ｅｎｔｐｄ２抗體之組合療法
JP2022548881A (ja) 2019-09-18 2022-11-22 ノバルティス アーゲー Ｅｎｔｐｄ２抗体、組合せ療法並びに抗体及び組合せ療法を使用する方法
CA3155930A1 (en) 2019-09-27 2021-04-01 Starkage Therapeutics SENESCENT CELL-ASSOCIATED ANTIGEN-BINDING DOMAINS, ANTIBODIES AND CHIMERIC ANTIGEN RECEPTORS COMPRISING THEM, AND USES THEREOF
WO2021116119A1 (en) 2019-12-09 2021-06-17 INSERM (Institut National de la Santé et de la Recherche Médicale) Antibodies having specificity to her4 and uses thereof
AU2021237790A1 (en) 2020-03-20 2022-10-13 INSERM (Institut National de la Santé et de la Recherche Médicale) Chimeric antigen receptor specific for human CD45RC and uses thereof
GB202004514D0 (en) 2020-03-27 2020-05-13 Inst De Medicina Molecular Joaeo Lobo Antunes Treatment of Immunosuppressive Cancer
KR102502287B1 (ko) 2020-04-17 2023-02-22 앱클론(주) 항-her2 어피바디 및 이를 스위치 분자로 이용하는 스위처블 키메라 항원 수용체
WO2021228956A1 (en) 2020-05-12 2021-11-18 INSERM (Institut National de la Santé et de la Recherche Médicale) New method to treat cutaneous t-cell lymphomas and tfh derived lymphomas
IL300528A (en) 2020-08-07 2023-04-01 Fortis Therapeutics Inc Immune conjugates targeting cd46 and methods of using them
KR102350655B1 (ko) 2020-10-13 2022-01-12 인센 주식회사 테스토스테론-특이적 어피바디 및 이의 용도
EP4229068A1 (en) 2020-10-13 2023-08-23 Avitide LLC Affinity ligand libraries of three-helix bundle proteins and uses thereof
EP4247496A1 (en) 2020-11-20 2023-09-27 Institut National de la Santé et de la Recherche Médicale (INSERM) Anti-cd25 antibodies
CA3199006A1 (en) 2020-11-20 2022-05-27 Inserm (Institut National De La Sante Et De La Recherche Medicale) Anti-cd25 antibodies
US20240108746A1 (en) 2020-12-16 2024-04-04 Molecular Partners Ag Novel slow-release prodrugs
EP4294542A1 (en) 2021-02-19 2023-12-27 Avitide LLC Aav2 affinity agents
CA3211368A1 (en) 2021-03-09 2022-09-15 Molecular Partners Ag Novel darpin based cd123 engagers
JP2024508969A (ja) 2021-03-09 2024-02-28 モレキュラー パートナーズ アクチェンゲゼルシャフト 新規のＤＡＲＰｉｎに基づくＣＤ３３エンゲージャ
WO2022190008A1 (en) 2021-03-09 2022-09-15 Molecular Partners Ag Protease cleavable prodrugs
CA3214757A1 (en) 2021-04-08 2022-10-13 Andreas Loew Multifuntional molecules binding to tcr and uses thereof
WO2023170296A1 (en) 2022-03-11 2023-09-14 Inserm (Institut National De La Sante Et De La Recherche Medicale) Nucleic acid system to specifically reprogram b and t cells and uses thereof
WO2024003380A1 (en) 2022-06-30 2024-01-04 Icm (Institut Du Cerveau Et De La Moelle Épinière) Vascular endothelial growth factor receptor-1 (vegfr-1) inhibitors for promoting myelination and neuroprotection
WO2024008755A1 (en) 2022-07-04 2024-01-11 Vib Vzw Blood-cerebrospinal fluid barrier crossing antibodies
WO2024052503A1 (en) 2022-09-08 2024-03-14 Institut National de la Santé et de la Recherche Médicale Antibodies having specificity to ltbp2 and uses thereof
WO2024077118A2 (en) 2022-10-06 2024-04-11 Bicara Therapeutics Inc. Multispecific proteins and related methods

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4954618A (en) * 1986-02-14 1990-09-04 Genex Corporation Cloned streptococcal genes encoding protein G and their use to construct recombinant microorganisms to produce protein G
US5312901A (en) * 1986-02-14 1994-05-17 Pharmacia Lkb Biotechnology Ab Cloned streptococcal genes encoding protein G and their use to construct recombinant microorganisms to produce protein G
US5229492A (en) * 1986-02-14 1993-07-20 Pharmacia Lkb Biotechnology Ab Cloned streptococcal genes encoding protein G and their use to construct recombinant microorganisms to produce protein G
US4879213A (en) * 1986-12-05 1989-11-07 Scripps Clinic And Research Foundation Synthetic polypeptides and antibodies related to Epstein-Barr virus early antigen-diffuse
US5084559A (en) * 1987-03-27 1992-01-28 Repligen Corporation Protein a domain mutants
US5767063A (en) * 1991-03-29 1998-06-16 Genentech, Inc. Human IL-8 receptor and antibodies thereto
SE9400088D0 (sv) * 1994-01-14 1994-01-14 Kabi Pharmacia Ab Bacterial receptor structures
US5877016A (en) * 1994-03-18 1999-03-02 Genentech, Inc. Human trk receptors and neurotrophic factor inhibitors

Also Published As

Publication number Publication date
PT739353E (pt) 2005-01-31
AU696186B2 (en) 1998-09-03
ATE279439T1 (de) 2004-10-15
EP0739353B1 (en) 2004-10-13
DE69533644T2 (de) 2005-02-17
JP2007308509A (ja) 2007-11-29
US6534628B1 (en) 2003-03-18
CA2181042C (en) 2008-04-15
CA2181042A1 (en) 1995-07-20
JP4089920B2 (ja) 2008-05-28
US5831012A (en) 1998-11-03
EP0739353A1 (en) 1996-10-30
JP4373461B2 (ja) 2009-11-25
AU1548795A (en) 1995-08-01
DE69533644D1 (de) 2004-11-18
JPH09508016A (ja) 1997-08-19
ES2225838T3 (es) 2005-03-16
WO1995019374A1 (en) 1995-07-20
JP2005263810A (ja) 2005-09-29
NZ278991A (en) 1997-04-24
WO1995019374A9 (en) 2006-04-13

Similar Documents

Publication Publication Date Title
SE9400088D0 (sv) Bacterial receptor structures
ATE377027T1 (de) Tetravalente antikörperkonstrukte
DE3750342D1 (de) Menschliches gamma-interferon-spezifisches Rezeptorprotein, Antikörper gegen dieses Protein, Verfahren zur Herstellung dieses Proteins und dieses Antikörpers und dieses Protein und diesen Antikörper enthaltende Zusammensetzungen.
DE69228701T2 (de) Fragmente von Prion Proteinen.
PT822199E (pt) Polipeptidos monopegilados no terminal-n e metodo para a sua preparacao
DK0758383T3 (da) Oplöselige polypeptidfraktioner af LAG-3-proteinet; fremgangsmåde til fremstilling; terapeutisk sammensætning; antiidiotypisk antistof
NZ521396A (en) Fusion proteins comprising two or more Neisseria polypeptides
DK0854917T3 (da) Transgene ikke-humane dyr, som kan producere heterologe antistoffer
DK1129186T3 (da) Et faktor VIII-polypeptid med faktor VIII:C-aktivitet
ES2153671T3 (es) Peptidos neuroactivos.
ATE395364T1 (de) Gegen procalcitonin gerichtete antikörper, ihre herstellung und verwendung
ATE360695T1 (de) Cortistatin: neuropeptide, zusammensetzungen und methoden
DE68925275T2 (de) Endotoxin-bindeprotein und dessen verwendung
ATE206621T1 (de) Il-8 antagonisten zur behandlung von asthma
DK0546087T3 (da) Proteinstruktur af plantetoksinet gelonin
PT625157E (pt) Epitopes p1a1 e p1a2 da gpiiia da plaqueta sua preparacao e utilizacao
DE69737476D1 (de) Neuer galaninrezeptor
DE69315989T2 (de) Aminoterminale prokollagen 1(i) peptide
DK453285A (da) Syntetisk signalsekvens og dens anvendelse, bl.a. til transportekspressioner af proteiner
DE59109235D1 (de) Peptide des HIV-gag Proteins, ihre Herstellung und Verwendung
NO991227L (no) PTX-sensitive G-proteiner, deres fremstilling og bruk
DK1208213T3 (da) Fremgangsmåde til fremstilling af proteiner i værtsceller under anvendelse af chaperoniner
FR2739622B1 (fr) Nouvelles proteines membranaires d&#39;helicobacter pylori
EA199800028A1 (ru) Винилсульфоксиды и способы их синтеза
DE3990097T1 (de) Immunoassays unter verwendung monoklonaler antikoerper, die gegen natuerliche bindende proteine gerichtet sind